AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05604183 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Test of cognitive ability on tablet computer with CoGNIT software
Description: The Principle Investigator or a trained medical nurse (under the supervision of the Principal Investigator) will give the patient to perform the digital cognitive test on a commercial tablet computer. The Principal Investigator or the medical nurse will be available for the patient to ask questions while the test is ongoing.
Study NCT05397236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine dexamethasone
Description: Patients received QL block with 20 ml of 0.25% bupivacaine (2,4)plus 2 ml of 8 mg dexamethasone plus 3 ml of 0.9% NS.
Study NCT05397236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine saline
Description: Patients received QL block with 20 ml of 0.25% bupivacaine (2,4)plus 5 ml of 0.9% NS.
Study NCT06559423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-ablative Er:YAG laser and high intensity Tesla magnetic stimulation (HITS)
Description: Patients will initially undergo three monthly intravaginal treatments with the Er:YAG laser. Six weeks after the final laser treatment, patients will receive six sessions of magnetic stimulation. During these sessions, patients will sit on a specialized chair that generates a therapeutic magnetic field.
Study NCT04941586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education in pain, Manual Therapy and Exercises
Description: twice a week, lasting 60 minutes, for one month
Study NCT04941586 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy and Exercises
Description: twice a week, lasting 40 minutes, for one month
Study NCT06083584 — intervention group
Intervention type: OTHER
Intervention: RNA sequencing
Description: RNA-Seq (Sureselect XT HS2 RNA) from patient blood sample
Study NCT05573802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab Mafodotin-Blmf
Description: Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder. Blmf will be delivered as IV solution over at least 30 minutes.
Study NCT05573802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered per os.
Study NCT05573802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered intravenously or per os.
Study NCT05573802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat
Description: Nirogacestat will be administrated each day for all subsequent cycles were Blmf is also administrated.
Study NCT05075369 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: water drinking test
Description: Water drinking test-glaucoma diagnostic test - marker for outflow facility reserve to detect IOP instability when the body ingests 800 ml of water within a 5 minute period of time
Study NCT05093205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: Tablets
Study NCT05093205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Tablets
Study NCT05093205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Syrup
Study NCT05093205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel & Ethinyl Estradiol
Description: Tablet
Study NCT06156644 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PFA
Description: Ablation to treat trail fibrillation
Study NCT05407623 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAX Good Behavior Game
Description: PAX GBG is packaged into ten specific tools that the teachers are trained to introduce in in their classroom management practice. The program introduces verbal and visual cues that facilitate prosocial and attentive behaviors One of the core elements of the program is the PAX-game, meaning that the children - while focusing on ordinary school tasks like math - get to play a game in teams where each team tries to make as few classroom rules infractions as possible during a certain period of time. The teams that succeed in achieving predetermined goals get a reward (often a fun and desirable activity) that serves as a reinforcer of prosocial and task-oriented behaviors.~Supervision is performed individually with each teacher and included that the PAX-trainer observes a lecture given by the teacher before each supervision session.
Study NCT05407623 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Count on Me!
Description: Count on me! is set in adventure game where the child has an avatar that travels thru different worlds/platforms by using their mathematical skills. The child starts of in the home of the avatar, in a house like environment, where the child discovers a magical map that brings the child into a different world called Numberia. During the adventures in Numberia the child learns that it has certain skills, called the mathemagical powers, that will be used to liberate Numberia from the evil Prince Claw that has captured all the beautiful things (e.g., the birds that used to sing in the forest).~Count on me! was developed within a behavior analytic framework using a nonlinear programming process.
Study NCT05407623 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Collegial Learning Community
Description: Collegial learning community is a feasible way of professional learning for teachers according to the five cyclical steps. The teachers go through the first step that is to assess the skill or knowledge gaps for students, using various data sources (for example testing, grades, surveys, student interviews). The second step is to reflect upon what skills the teacher needs to acquire in order to help the students to meet the goals. The third step is to deepen the professional knowledge and skills. The fourth step is engaging the students in the new practice, and in the fifth step to evaluate the impact the new practice has had on student outcomes.~In Collegial learning community teachers take help from their peers in each of these steps in a structured way. For example, way of deepening tacit or procedural knowledge (in step two) is to visit a colleague during class and make observations on their classroom practice.
Study NCT05296967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: chewing
Description: patients are asked to chew chewing gum X 3/ day
Study NCT05916872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental group
Description: Patients will receive Proprioceptive Neuromuscular Facilitation (contract-relax) technique with EMS
Study NCT05916872 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: Patients will receive conventional therapy.
Study NCT04738955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin Sodium
Description: micafungin sodium ≥ 100, \<200mg/time, once a day, intravenous drip. Low dose group
Study NCT05264350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sialic acid nasal spray
Description: The nasal spray will be self administered twice daily for 8 weeks.
Study NCT05264350 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic Saline Nasal Spray
Description: The nasal spray will be self administered twice daily for 8 weeks.
Study NCT04816240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: 5mg thrice daily and will be increased every 3 days upto 15 mg thrice daily with target MAP (>75 mm and \<90)
Study NCT04816240 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Description: 80grams/week for 2 weeks followed by 40gram/week
Study NCT04816240 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albumin
Description: 80grams/week for 2 weeks followed by 40gram/week
Study NCT04816240 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment
Study NCT04816240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment
Study NCT04816240 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04715152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACB group
Description: Patients will receive ultrasound-guided (USG) ACB with bupivacaine and dexamethasone 30 minutes before spinal anesthesia and sham intra-articular normal saline
Study NCT04715152 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IA group
Description: Patients will receive intra-articular bupivacaine and dexamethasone at the end of surgery and sham USG-ACB with normal saline
Study NCT06426004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patients will receive NPH education
Description: Patients will benefit from the Hydrocephalus Association's (HA) educational strategy for idiopathic normal pressure hydrocephalus (iNPH) emphasizes patient collaboration in the development of educational materials specifically for this condition. HA has a library of assets that include PowerPoint presentations, videos, and online and print educational materials. There will be also in-person outreach resulting recruitment, website (the study website and HA website), webform (with a symptom of gait, dementia, and bladder symptoms), YouTube videos. The investigators will also go to the communities like senior centers, health fair, and churches, then we will give a talk about iNPH. These resources will be carefully adjusted to suit low-income demographics, guided by feedback from Baltimore audiences and HA's iNPH volunteers.
Study NCT06426004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: primary care physicians (PCPs) will receive professional NPH education
Description: A comprehensive professional development program for PCPs and CHWs, featuring presentations, educational videos, webinars, and tools on iNPH diagnosis, treatment, and care management. Provider Continuing Medical Education (CME) credits will be offered for in-person lectures, aiming to equip PCPs with the skills needed to address iNPH in low-income settings effectively
Study NCT06426004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A community health worker will assist PCP
Description: A community health worker will assist PCP to identify barriers and help overcome these barriers in order for patient to access iNPH care.
Study NCT04702737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarlatamab
Description: Tarlatamab will be administered as an intravenous (IV) infusion.
Study NCT04845217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peppermint oil
Description: Enteric coated peppermint oil taken by mouth three times daily for 8 weeks.
Study NCT04845217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Coconut Oil
Description: Enteric coated coconut oil taken by mouth three times daily for 8 weeks
Study NCT05641883 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CardiaMend with antiarrhythmic
Description: Pericardial patch with antiarrhythmic drug (amiodarone) topically applied
Study NCT04078932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Violence Prevention Conversation Script to Discuss Safely Navigating Police Encounters
Description: A conversation script to facilitate conversations on safely navigating police encounters as anticipatory guidance and violence prevention strategy. The conversation script will be created using expert recommendations from existing resources and using recommendations (determined from focus groups) from black male youth and their caregivers. The script will be patient-centered.
Study NCT05857891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human erythropoietin injection
Description: Each subject in the test group received 40000iu of human erythropoietin intravenously
Study NCT05857891 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9%NaCl
Description: Each subject in the control group was injected with an equal volume of 0.9%NaCl
Study NCT04880330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryo-Auriculotherapy
Description: 1 session of cryo-auriculotherapy with device with nitrous oxyde on 15 auricular points.
Study NCT04880330 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: 1 session of cryo-auriculotherapy with device without nitrous oxyde on 15 auricular points.
Study NCT05457582 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus high-intensity statin
Description: Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen, Q2W, and oral administration of rosuvastatin (20 mg, once daily).
Study NCT05457582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCSK 9 Inhibitor plus high-intensity statin
Description: Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen, Q2W, and oral administration of rosuvastatin (20 mg, once daily).
Study NCT06177275 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of BLX implants 2 mm sub-crestal i
Description: Placement of BLX implants 2 mm sub-crestal in single missing anterior or premolar teeth in the esthetic zone with immediate provisionalization via a straight emergence profile temporary crown on a temporary abutment.
Study NCT06177275 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of BLX implants equicrestal
Description: Placement of BLX implants equicrestal in single missing anterior or premolar teeth in the esthetic zone with immediate provisionalization via a straight emergence profile temporary crown on a temporary abutment.
Study NCT04589195 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: The intervention includes four weeks of MT application use, accessed via phone or computer, consisting of 15-minute daily mindfulness practices 5 days a week.
Study NCT04589195 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Training
Description: The intervention includes four weeks of MT application use, accessed via phone or computer, consisting of 15-minute daily mindfulness practices 5 days a week.
Study NCT06314022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application for colonoscopy preparation instructions
Description: The APP will also consider the comorbidities and drugs of each patient. It can be adapted to the different types of laxative (4, 2 or 1 litre) and notify the need to discontinue anticoagulant and/or antiplatelet treatments by contacting with the primary care physician. Additionally, the application may ask short questions to the patient to control the laxative intake instruction. The user must confirm the appointment 48 hours in advance.
Study NCT05306639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: rehabilitation sessions using spinal magnetic stimulation or neuromodulation
Study NCT05044221 — intervention group
Intervention type: OTHER
Intervention: Former ICU patient and caregiver workshops
Description: In depth interviews and workshops will be conducted with individuals enrolled in the study.
Study NCT05044221 — intervention group
Intervention type: OTHER
Intervention: Health care professional workshops
Description: In depth interviews and workshops will be conducted with individuals enrolled in the study.
Study NCT04728763 — intervention group
Intervention type: OTHER
Intervention: Protein profile
Description: Analysis of the protein content by proteomics of bronchoalveolar lavage
Study NCT06228963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple therapy for eradication of Helicobacter Pylori and Orelabrutinib
Description: Triple therapy for H. pylori (oral administration for 2 weeks, followed by a 1-week break) plus Orelabrutinib for 8 weeks (or until progression, intolerable toxicity, death, or withdrawal from the study)
Study NCT06228963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triple therapy for eradication of Helicobacter Pylori
Description: Triple therapy for H. pylori (oral administration for 2 weeks, followed by a 1-week break)
Study NCT05327491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Oral Tablet
Study NCT05117671 — intervention group
Intervention type: OTHER
Intervention: data collection to classify infection status
Description: Review of medical records of all selected cases (TKA/THA patients) to classify infection status according to different classifications (EBJIS, MSIS/ICM 2013, ICM 2018).
Study NCT05346445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine 20 MG
Description: Participants received non-hormonal treatment with fluoxetine.
Study NCT05346445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram 20mg
Description: Participants received non-hormonal treatment with citalopram.
Study NCT04991831 — intervention group
Intervention type: DEVICE
Intervention: Unilateral thalamotomy
Description: Unilateral thalamotomy using focused ultrasound for the treatment of medication-refractory tremor dominant idiopathic Parkinson's Disease.
Study NCT06327230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Epidural Analgesia
Description: Thoracic epidural analgesia is performed by a standardized anesthesia team. Patients are positioned in the lateral decubitus position, and routine disinfection is performed. The puncture site is selected at the T7-T9 level. When encountering sudden disappearance of resistance and appearance of negative pressure during needle advancement, it is determined that the needle has entered the epidural space. After confirming needle tip placement in the epidural space with a test dose, an epidural catheter is inserted approximately 3-5cm cephalad and securely fixed in place. The test dose consists of 3 mL of 1% lidocaine injection solution, administered to observe the level of anesthesia, confirming the effectiveness and safety of the epidural anesthesia. Subsequently, a maintenance regimen of 0.15% ropivacaine 250mL with 2.5mg of hydroma.
Study NCT05511038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Injection, 2mg (equivalent to 50 µL solution for injection)
Study NCT05621356 — intervention group
Intervention type: OTHER
Intervention: A nasal fluid Basophil Activation Test (BAT)
Description: a BAT technique for monitoring the inhibitory effect of nasal fluid on basophil activation.
Study NCT05601245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High voltage pulsed current
Description: The treatment session duration is 45 minutes (Reverse the polarity after the first 22 minutes)
Study NCT05601245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microcurrent therapy
Description: The treatment session duration is 40 minutes.
Study NCT06363162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry or genetic test
Description: Perform two diagnostic methods on the same sample
Study NCT05294029 — intervention group
Intervention type: OTHER
Intervention: standard of care for patients with neuromotor disability
Description: clinical examination, radiological, biological and physiological examinations.
Study NCT06016816 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral endoscopic sphenopalatine ganglion block
Description: After the induction of general anesthesia, one group (Group: 1) will be administered 8mg dexamethasone and 10mg bupivacaine submucosal,
Study NCT06016816 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo group (group:2) will be administered 4 cc saline. aspects will be evaluated.
Study NCT06226402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline 3% nebulizer
Description: Patients will receive the standard pharmacotherapy + hypertonic saline 3% (5ml) nebulizer /8hr.
Study NCT06226402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous hypertonic saline 3%
Description: Patients will receive the standard pharmacotherapy + hypertonic saline 3% intravenous over 24 hours to maintain plasma Na level between 145-150 mEq/L.
Study NCT06166836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D1553
Description: D1553 orally taken，600mg twice a day
Study NCT06166836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D1553
Description: D1553 orally taken，600mg twice a day
Study NCT06166836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018（Ifebemtinib）
Description: IN10018 orally taken once daily at approximately the same time each day
Study NCT05002920 — intervention group
Intervention type: PROCEDURE
Intervention: alveolar bone grafting
Description: the surgery of alveolar bone graft for alveolar defect in cleft patients
Study NCT05320497 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transparent cap
Description: Add a self-made transparent cap (made by cutting a silicone drainage tube) to the end of the SpyGlass choledochoscope, and then perform routine choledochoscopy and biopsy operations
Study NCT05154370 — intervention group
Intervention type: DRUG
Intervention: Intravenous steroid
Description: This study does not limit treatment methods. Patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. Immunomodulatory therapies are necessary for the remission stage. All drugs are used in accordance with relevant guidelines.